Koss Olinger Consulting LLC Takes $235,000 Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Koss Olinger Consulting LLC purchased a new stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) in the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 370 shares of the biopharmaceutical company’s stock, valued at approximately $235,000.

Other hedge funds have also added to or reduced their stakes in the company. Marietta Wealth Management LLC increased its stake in Regeneron Pharmaceuticals by 30.2% in the first quarter. Marietta Wealth Management LLC now owns 10,778 shares of the biopharmaceutical company’s stock valued at $6,836,000 after acquiring an additional 2,501 shares during the last quarter. GAMMA Investing LLC grew its stake in shares of Regeneron Pharmaceuticals by 89,825.0% in the first quarter. GAMMA Investing LLC now owns 815,620 shares of the biopharmaceutical company’s stock worth $517,291,000 after purchasing an additional 814,713 shares during the last quarter. China Universal Asset Management Co. Ltd. grew its stake in shares of Regeneron Pharmaceuticals by 3.9% in the first quarter. China Universal Asset Management Co. Ltd. now owns 25,629 shares of the biopharmaceutical company’s stock worth $16,255,000 after purchasing an additional 955 shares during the last quarter. KBC Group NV grew its stake in shares of Regeneron Pharmaceuticals by 9.4% in the first quarter. KBC Group NV now owns 149,440 shares of the biopharmaceutical company’s stock worth $94,779,000 after purchasing an additional 12,793 shares during the last quarter. Finally, Lmcg Investments LLC grew its stake in shares of Regeneron Pharmaceuticals by 231.3% in the first quarter. Lmcg Investments LLC now owns 14,481 shares of the biopharmaceutical company’s stock worth $9,184,000 after purchasing an additional 10,110 shares during the last quarter. 83.31% of the stock is owned by institutional investors.

Analyst Ratings Changes

A number of analysts have commented on the stock. Royal Bank Of Canada upped their price target on shares of Regeneron Pharmaceuticals from $688.00 to $695.00 and gave the company a “sector perform” rating in a research report on Monday, August 4th. Morgan Stanley restated an “overweight” rating and issued a $761.00 target price (up previously from $754.00) on shares of Regeneron Pharmaceuticals in a report on Friday, August 1st. The Goldman Sachs Group lowered their target price on shares of Regeneron Pharmaceuticals from $917.00 to $804.00 and set a “buy” rating on the stock in a report on Wednesday, April 30th. Bank of America lowered their target price on shares of Regeneron Pharmaceuticals from $575.00 to $547.00 and set an “underperform” rating on the stock in a report on Thursday, April 17th. Finally, Guggenheim lifted their target price on shares of Regeneron Pharmaceuticals from $810.00 to $815.00 and gave the stock a “buy” rating in a research report on Friday, August 1st. One equities research analyst has rated the stock with a sell rating, seven have issued a hold rating, sixteen have issued a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $841.30.

Regeneron Pharmaceuticals Trading Up 0.6%

Shares of REGN opened at $563.00 on Monday. Regeneron Pharmaceuticals, Inc. has a 1-year low of $476.49 and a 1-year high of $1,211.20. The company has a current ratio of 4.60, a quick ratio of 3.72 and a debt-to-equity ratio of 0.09. The firm’s 50-day moving average price is $536.80 and its 200-day moving average price is $598.52. The firm has a market capitalization of $59.67 billion, a price-to-earnings ratio of 14.19, a PEG ratio of 1.91 and a beta of 0.33.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings data on Friday, August 1st. The biopharmaceutical company reported $12.89 EPS for the quarter, topping the consensus estimate of $8.43 by $4.46. The business had revenue of $3,675,600 billion for the quarter, compared to analyst estimates of $3.30 billion. Regeneron Pharmaceuticals had a net margin of 31.37% and a return on equity of 15.06%. Regeneron Pharmaceuticals’s quarterly revenue was up 3.6% on a year-over-year basis. During the same quarter in the previous year, the firm posted $11.56 earnings per share. Sell-side analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current year.

Regeneron Pharmaceuticals Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Wednesday, September 3rd. Stockholders of record on Monday, August 18th will be paid a $0.88 dividend. This represents a $3.52 annualized dividend and a dividend yield of 0.6%. The ex-dividend date is Monday, August 18th. Regeneron Pharmaceuticals’s dividend payout ratio is currently 8.87%.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.